XZXiaoping Zhang

Xiaoping Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoping Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Albert Dorr

    XIQ Coordination, Inc, Fort Myers, Florida

    2 shared publications
  • Anne Bertasso

    Hoffmann–La Roche, Inc, Nutley, New Jersey (Dr Zhang, Dr Lin, Ms Bertasso, Mr Kolis, Dr Salgo, Dr Patel)

    1 shared publication
  • Benoite Kaeser

    Hoffmann-La Roche, Ltd., Basel, Switzerland

    1 shared publication
  • Christophe Schmitt

    Hoffmann-La Roche, Ltd., Basel, Switzerland,1 Hoffman-La Roche, Inc., Nutley, New Jersey,2 Institut de Pharmacologie Clinique, Roche, Strasbourg, France3

    1 shared publication
  • Claire Evans

    Roche Products Ltd, Welwyn Garden City, UK

    1 shared publication
  • Elke Zwanziger

    Hoffmann-La Roche, Ltd., Basel, Switzerland,1 Hoffman-La Roche, Inc., Nutley, New Jersey,2 Institut de Pharmacologie Clinique, Roche, Strasbourg, France3

    1 shared publication

Latest Publications

  • Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir

    by Benoite Kaeser, Hagen Zandt, Fabrice Bour, Elke Zwanziger, Christophe Schmitt, Xiaoping Zhang

    Saquinavir, a potent human immunodeficiency virus protease inhibitor, is extensively metabolized by CYP3A4. Saquinavir is coadministered with ritonavir, a strong CYP3A4 inhibitor, to boost its exposure. Ketoconazole is a potent CYP3A inhibitor. The objectives of this study were to investigate the effect of ketoconazole on the pharmacokinetics of saquinavir/ritonavir and vice versa using the approved dosage regimens of saquinavir/ritonavir at 1,000/100 mg twice daily and ketoconazole at 200 mg once daily. This was an open-label, randomized two-arm, one-sequence, two-period crossover study in healthy subjects. In study arm 1, 20 subjects received saquinavir/ritonavir treatment alone for 14 days, followed in combination with ketoconazole treatment for 14 days. In arm 2, 12 subjects received ketoconazole treatment for 6 days, followed in combination with saquinavir/ritonavir treatment for 14 days. The pharmacokinetics were assessed on the last day of each treatment (days 14 and 28 in arm 1 and days 6 and 20 in arm 2). The exposures C max and the area under the concentration-time curve from 0 to 12 h (AUC 0-12 ) of saquinavir and ritonavir with or without ketoconazole were not substantially altered after 2 weeks of concomitant dosing with ketoconazole. The C max and AUC 0-12 of ketoconazole, dosed at 200 mg once daily, were increased by 45% (90% confidence interval = 32 to 59%) and 168% (90% confidence interval = 146 to 193%), respectively, after 2 weeks of concomitant dosing with ritonavir-boosted saquinavir (1,000 mg of saquinavir/100 mg of ritonavir given twice daily). The greater exposure to ketoconazole when given in combination with saquinavir/ritonavir was not associated with unacceptable safety or tolerability. No dose adjustment for saquinavir/ritonavir (1,000/100 mg twice daily) is required when coadministered with 200 mg of ketoconazole once daily, and high doses of ketoconazole (>200 mg/day) are not recommended.


  • Population Pharmacokinetics of Enfuvirtide in HIV‐1‐Infected Pediatric Patients Over 48 Weeks of Treatment

    by Xiaoping Zhang, Tiffany Lin, Anne Bertasso, Claire Evans, Albert Dorr, Stanley J. Kolis, Miklos Salgo, Indravadan Patel

    The objective of this study was to characterize the population pharmacokinetics of enfuvirtide in HIV‐1‐infected children and adolescents. HIV‐infected patients received combination antiretroviral therapy, including enfuvirtide 2.0 mg/kg subcutaneously, twice daily. Serial and trough blood samples were collected up to 48 weeks. NONMEM was used for population pharmacokinetic analysis. Enfuvirtide exposure was calculated from individual parameter estimates derived from the final model. A total of 218 samples from 43 patients were included in the analysis. Enfuvirtide plasma concentration–time data were described by a 1‐compartment model with first‐order absorption and elimination. The addition of each subject's actual body weight as a covariate affected CL/F but not V/F or Ka. The population CL/F, V/F, and Ka for a 33‐kg reference patient was 1.31 L/h, 2.31 L, and 0.105 h−1, respectively. The final model was CL/F (L/h) = 1.31 · (body weight/33 [kg])0.721. Age did not affect enfuvirtide exposure. These results confirm the appropriateness of body weight–based pediatric enfuvirtide dosing.


  • Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1?infected patients*1

    by X Zhang

    Enfuvirtide is the first drug to block human immunodeficiency virus type 1 (HIV-1) glycoprotein 41-mediated viral fusion to host cells. This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients. An open-label, 1-sequence crossover study was conducted in 12 HIV-1-infected adults, by use of a 5-drug cocktail consisting of caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin to assess the activities of CYP1A2, CYP2E1, CYP3A4, CYP2D6, and CYP2C19, respectively. Dapsone was used to assess N-acetyltransferase activity. Patients received a single dose of the cocktail alone on day -15 and another together with enfuvirtide on day 6. Enfuvirtide (90 mg subcutaneously) was administered twice daily on days 1 to 7. Phenotypic index parameters were estimated and analyzed by ANOVA with factors subject and day (-15 and 6). The phenotypic index parameters, with and without enfuvirtide, for CYP3A4 (0.33 versus 0.34; 90% confidence interval [CI] for ratio of least squares means, 0.88-1.09), CYP2D6 (0.72 versus 0.71; 90% CI, 0.97-1.06), and N-acetyltransferase (0.35 versus 0.39; 90% CI, 0.82-0.98) were bioequivalent. The phenotypic index parameters, with and without enfuvirtide, for CYP1A2 (0.76 versus 0.81; 90% CI, 0.71-1.17), CYP2E1 (1.3 versus 1.2; 90% CI, 0.87-1.29), and CYP2C19 (93 versus 81.8; 90% CI, 0.98-1.28) were not bioequivalent but were not substantially different. Enfuvirtide had no clinically important effect on the metabolism of probe drugs mediated by CYP3A4, CYP2D6, or N-acetyltransferase and had little effect on the metabolism of drugs mediated by CYP1A2, CYP2E1, or CYP2C19. The potential for interactions between enfuvirtide and concomitantly administered drugs metabolized by the CYP enzymes tested in this study is low.


  • Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patientswith human immunodeficiency virus: Inverse Gaussian density absorption and 2‐compartment disposition*

    by Xiaoping Zhang, Keith Nieforth, Jean‐Marie Lang, Regine Rouzier‐Panis, Jacques Reynes, Albert Dorr, Stanley Kolis, Mark R. Stiles, Tosca Kinchelow, Indravadan H. Patel

    Objective: Enfuvirtide (T‐20) is the first of a novel class of human immunodeficiency virus (HIV) drugs that block gp41‐mediated viral fusion to host cells. The objectives of this study were to develop a structural pharmacokinetic model that would adequately characterize the absorption and disposition of enfuvirtide pharmacokinetics after both intravenous and subcutaneous administration and to evaluate the dose proportionality of enfuvirtide pharmacokinetic parameters at a subcutaneous dose higher than that currently used in phase III studies.Methods: Twelve patients with HIV infection received 4 single doses of enfuvirtide separated by a 1‐week washout period in an open‐label, randomized, 4‐way crossover fashion. The doses studied were 90 mg (intravenous) and 45 mg, 90 mg, and 180 mg (subcutaneous). Serial blood samples were collected up to 48 hours after each dose. Plasma enfuvirtide concentrations were measured with use of a validated liquid chromatography‐tandem mass spectrometry method.Results: Enfuvirtide plasma concentration‐time data after subcutaneous administration were well described by an inverse Gaussian density function‐input model linked to a 2‐compartment open distribution model with first‐order elimination from the central compartment. The model‐derived mean pharmacokinetic parameters (±SD) were volume of distribution of the central compartment (3.8 ± 0.8 L), volume of distribution of the peripheral compartment (1.7 ± 0.6 L), total clearance (1.44 ± 0.30 L/h), intercompartmental distribution (2.3 ± 1.1 L/h), bioavailability (89% ± 11%), and mean absorption time (7.26 hours, 8.65 hours, and 9.79 hours for the45‐mg, 90‐mg, and 180‐mg dose groups, respectively). The terminal half‐life increased from 3.46 to 4.35hours for the subcutaneous dose range from 45 to 180 mg.Conclusions: An inverse Gaussian density function‐input model linked to a 2‐compartment open distribution model with first‐order elimination from the central compartment was appropriate to describe complex absorption and disposition kinetics of enfuvirtide plasma concentration‐time data after subcutaneous administration to patients with HIV infection. Enfuvirtide was nearly completely absorbed from subcutaneous depot, and pharmacokinetic parameters were linear up to a dose of 180 mg in this study.Clinical Pharmacology & Therapeutics (2002) 72, 10–19; doi: 10.1067/mcp.2002.125945